Patents by Inventor Philip J. Fay
Philip J. Fay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9072722Abstract: The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.Type: GrantFiled: November 30, 2012Date of Patent: July 7, 2015Assignee: University of RochesterInventors: Philip J. Fay, Hironao Wakabayashi
-
Publication number: 20150037301Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.Type: ApplicationFiled: October 19, 2014Publication date: February 5, 2015Applicant: UNIVERSITY OF ROCHESTERInventors: Philip J. Fay, Hironao Wakabayashi
-
Patent number: 8865154Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.Type: GrantFiled: December 27, 2013Date of Patent: October 21, 2014Assignee: University of RochesterInventors: Philip J. Fay, Hironao Wakabayashi
-
Publication number: 20140120071Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.Type: ApplicationFiled: December 27, 2013Publication date: May 1, 2014Applicant: UNIVERSITY OF ROCHESTERInventors: Philip J. FAY, Hironao WAKABAYASHI
-
Publication number: 20140056861Abstract: The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.Type: ApplicationFiled: October 11, 2013Publication date: February 27, 2014Applicant: University of RochesterInventors: Philip J. Fay, Hironao Wakabayashi
-
Patent number: 8637448Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.Type: GrantFiled: September 13, 2011Date of Patent: January 28, 2014Assignee: University of RochesterInventors: Philip J. Fay, Hironao Wakabayashi
-
Patent number: 8338571Abstract: The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.Type: GrantFiled: July 25, 2008Date of Patent: December 25, 2012Assignee: University of RochesterInventors: Philip J. Fay, Hironao Wakabayashi
-
Patent number: 8183345Abstract: The present invention relates to a recombinant factor VIII that is characterized by one or more mutations within a region surrounding an activated protein C cleavage site, which one or more mutations result in a reduced rate of inactivation by activated protein C. Isolated nucleic acid molecules, recombinant expression vectors, and host cells suitable for expression of the recombinant factor VIII are also disclosed. The recombinant factor VIII can be used for the treatment of clotting disorders, such as hemophilia A.Type: GrantFiled: July 25, 2008Date of Patent: May 22, 2012Assignee: University of RochesterInventors: Philip J. Fay, Hironao Wakabayashi, Fatbardha Varfaj
-
Publication number: 20120065136Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.Type: ApplicationFiled: September 13, 2011Publication date: March 15, 2012Applicant: UNIVERSITY OF ROCHESTERInventors: Philip J. FAY, Hironao WAKABAYASHI
-
Patent number: 7855274Abstract: The present invention relates to recombinant factor VIII having a specific activity that is higher than that of the corresponding wild-type factor VIII. The present invention also relates to methods of making and using the recombinant factor VIII. The present invention also relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.Type: GrantFiled: December 2, 2004Date of Patent: December 21, 2010Assignee: University of RochesterInventors: Philip J. Fay, Hironao Wakabayashi
-
Publication number: 20090118185Abstract: The present invention relates to a recombinant factor VIII that is characterized by one or more mutations within a region surrounding an activated protein C cleavage site, which one or more mutations result in a reduced rate of inactivation by activated protein C. Isolated nucleic acid molecules, recombinant expression vectors, and host cells suitable for expression of the recombinant factor VIII are also disclosed. The recombinant factor VIII can be used for the treatment of clotting disorders, such as hemophilia A.Type: ApplicationFiled: July 25, 2008Publication date: May 7, 2009Applicant: UNIVERSITY OF ROCHESTERInventors: Philip J. Fay, Hironao Wakabayashi
-
Publication number: 20090118184Abstract: The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.Type: ApplicationFiled: July 25, 2008Publication date: May 7, 2009Applicant: UNIVERSITY OF ROCHESTERInventors: Philip J. Fay, Hironao Wakabayashi
-
Publication number: 20040126856Abstract: Novel agents that inhibit the interaction of factor VIIIa with factor IXa in newly discovered regions of interaction, Region 2 and Region 3, are disclosed. The novel polypeptides or derivatives of polypeptides prevent activation of factor X and have anti-coagulation activity. The agents include polypeptides or polypeptide derivatives that are homologous to factor VIIIa or factor IXa in Region 2 and/or Region 3, as well as agents that are not homologous, such as antibodies Region 2 or Region 3. Pharmaceutical compositions comprising the agents are also disclosed. Methods of treatment are also disclosed, comprising the step of determining whether the compound displaces the interaction of the above agent from factor VIII or factor IX. Methods for preventing coagulation in a blood sample are also disclosed. These methods comprise adding the above agent to the sample.Type: ApplicationFiled: January 15, 2004Publication date: July 1, 2004Inventors: Paul S. Bajaj, Philip J Fay
-
Patent number: 4614795Abstract: Highly purified, biologically active Human Factor VIII:C having specific activities of about 4000-8000 units per milligram of protein is prepared. In the method of preparation, an AHF concentrate is solubilized or equilibrated in an aqueous medium and treated to change the effective Stokes' radius of the Factor VIII:C to an apparently low value and then subjected to a separation from the concentrate. Treatment of the highly purified Factor VIII:C with a mixture of glycosidases causes substantial removal of carbohydrate side chains without reduction of procoagulant activity and with retention of significant in vivo survival time.Type: GrantFiled: January 13, 1984Date of Patent: September 30, 1986Assignee: University of RochesterInventors: Stephen I. Chavin, Philip J. Fay
-
Patent number: 4495175Abstract: Highly purified, biologically active Human Antihemophilic Factor (AHF) preparations are prepared having specific activities of about 4000-8000 units per milligram of AHF. In the method of preparation an AHF concentrate, prepared by fractionation of plasma to partially remove fibrinogen, fibronectin and other plasma components is subjected to a separation on the basis of Stokes' radius to separate AHF from the bulk of remaining proteins in the AHF concentrate. The pooled fractions containing AHF activity are concentrated by precipitation with ammonium sulfate, sodium sulfate, etc., by diafiltration, by PEG addition, or the like. The concentrate, is solubilized or equilibrated in an aqueous medium and treated to change the effective Stokes' radius of the AHF to an apparently low value and then subjected to a separation from the concentrate. The AHF pool from above is treated to remove cations by dialysis against an appropriate buffer of lower ionic strength and chromatographed on an anion-exchange medium.Type: GrantFiled: August 5, 1982Date of Patent: January 22, 1985Assignee: University of RochesterInventors: Stephen I. Chavin, Philip J. Fay